ClinicSpeak & NeuroSpeak: sequencing DMTs switching from natalizumab to alemtuzumab
…
ClinicSpeak: natalizumab or alemtuzumab?
…
Stuart Schlossman
NATALIZUMAB MISSES ENDPOINT IN SECONDARY PROGRESSIVE MS
…
Stuart Schlossman
Tysabri No Help in SPMS – Drug didn’t reduce disability progression but may benefit upper limb function
…
Stuart Schlossman
EMA advocates more regular MRIs for MS patients on Biogen’s mAb Tysabri
By Gareth MacDonald+, 17-Feb-2016 Multiple sclerosis patients taking Tysabri (natalizumab) who are deemed to be at high risk for the lethal…
Stuart Schlossman
MS Neurologist Argues for Continued Use of Natalizumab as Disease Treatment
In a recent study of more than 1,200 patients with multiple sclerosis (MS), a research team reported that treatment with the…
Stuart Schlossman
Study Shows That People with MS Taking Natalizumab Develop Antibodies to the JC Virus at Higher Than Normal Rates, Emphasizing Need for Regular Monitoring
January 27, 2016 A study by researchers in Germany and France observed changes in JC virus antibody status in two…
Stuart Schlossman
Natalizumab ( Tysabri ) Reported To Be a Safe and Effective Therapy for Pediatric Multiple Sclerosis
October 1, 2015 A new study recently published in the journal BMC Neurology revealed that natalizumab (TYSABRI) is a safe…
Stuart Schlossman
Possible JC Virus Vaccination Offers Important Implications for MS Treatment
Two studies recently published in the journal Science Translational Medicine, revealed a possible new vaccine treatment for JC virus with important…
Stuart Schlossman
New Mouse Model Better Represents JC Virus That Infects MS Patients
Posted by: Maureen Newman November 24, 2014 Researchers in the laboratory of Steve Goldman, MD, PhD, Co-Director of University…
Stuart Schlossman
